How Is the Retinal Gene Therapy Pipeline Building on Luxturna's Success?
Retinal gene therapy and the AAV ocular success story — the application of subretinal and intravitreal AAV delivery to inherited retinal dystrophies and age-related macular degeneration — building on Luxturna's (voretigene neparvovec) landmark success as the first FDA-approved gene therapy for an inherited retinal dystrophy — creating the most clinically advanced and...
0 Comments
0 Shares
25 Views